Blood/hematologic cancers most often begin in the bone marrow where blood is produced. Stem cells in the bone marrow develop into white blood cells, red blood cells, or platelets. Blood cancers occur when uncontrolled growth of abnormal blood cells overtakes the development of normal blood cells and interferes with the regular functions of these cells. Blood cancers fall into three categories: leukemia, lymphoma, and myeloma.
Developing quality improvement programs that aim to reduce disparities and improve the standard of care received by patients with blood/hematologic cancers are a key priority in ACCC’s educational portfolio. Leverage our recent research and explore practical, actionable resources to implement in your cancer program or practice today.
Three specialists in multiple myeloma care share their experiences that may help other providers and patients move smoothly through this time of transition while maintaining high quality care.
Explores challenges related to COVID-19 vaccination in patients with Chronic Lymphocytic Leukemia (CLL).
The pandemic has heightened the distress patients with chronic lymphocytic leukemia (CLL) are experiencing and taken its toll on providers. Join us for a discussion on strategies and solutions to these ubiquitous challenges and the path forward for providers and patient care.
This webinar is part of the Returning to Practice in the Post COVID-19 Era: Resources for Treating Chronic Lymphocytic Leukemia education project. Funding & support provided by AbbVie.
Panelists discussed considerations for resuming pre-pandemic level visits and procedures for patients with CLL, AML, and Multiple Myeloma. Panelists also discussed their wins and challenges with providing care to respective patients in a pandemic.
Clinical updates on MRD testing for Chronic Lymphocytic Leukemia (CLL) and the importance of incorporating it into the treatment plan.
This education project will help cancer programs and practices transition from pre- to post-pandemic response by showcasing the solutions that have worked for practices that have successfully adapted their services to the restrictions imposed by COVID-19.
To help cancer practices prepare for an expected increase in undiagnosed patients and a surge in upstaged patients, this project aims to teach care team members short- and long-term solutions to operational challenges as the pandemic recedes, paying special attention to traditionally underserved patient populations.
Join expert faculty in the field of hematologic malignancies and gain important and practical information for the assessment of measurable residual disease (MRD) as part of routine clinical practice for their patients with chronic lymphocytic leukemia (CLL).
The presentation will be valuable for understanding the impact of MRD on treatment decisions and practice patterns, which has promise to lead to major improvements in outcomes for CLL patients in the very near future.
ACCC is committed to help ensure access to recommended care for patients who receive treatment for multiple myeloma or acute lymphoblastic leukemia through a partnership with the American Cancer Society and Project ECHO. The educational focus will be on bringing the latest content knowledge and best practices in the treatment of these hematological cancer patients to your cancer care team.
Participation in the TeleECHO Clinic is free. The clinics will convene by videoconference each month.
B-cell Acute Lymphoblastic Leukemia (ALL) was the first disease state with an FDA-approved treatment for MRD. This project will help lay the foundation for MRD testing in patients with B-cell ALL to create better-informed multidisciplinary cancer care teams. Ultimately, this work will showcase not only the importance of MRD testing, but also how it can be best integrated into the cancer care workflow.
The ACCC Multidisciplinary Acute Lymphocytic Leukemia (ALL) Care education project seeks to identify key barriers to and opportunities for improvement in the cancer care team’s support of patients diagnosed with ALL, including utilization of MRD testing, detection, and monitoring.
Read ACCC’s environmental scan including an overview of the current landscape for ALL diagnosis and treatment, along with opportunities to improve patient care.
The ACCC Multidisciplinary Chronic Lymphocytic Leukemia (CLL) Care education project seeks to understand the current landscape of treating CLL in the community, identify effective practices and potential gaps in provider and patient communication, and provide peer-to-peer learning and resources for increased awareness and best practices in multidisciplinary care for patients with CLL.
Guided by an expert Advisory Committee, this ACCC education project provides support to multidisciplinary cancer care teams in diagnosing, testing, and treating patients with multiple myeloma. This project serves to:
The ACCC education project, The Transplant Treatment Path: Optimizing Patient-Centered Care for ASCT in Multiple Myeloma, explores steps for improving provider communication to optimize the treatment of multiple myeloma patients in the community cancer center pre- and post-autologous stem cell transplant (ASCT).
Sources: American Cancer Society; American Society of Hematology; Leukemia & Lymphoma Society; National Cancer Institute.